A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Suzanne Leijen, Patricia M. M. B. Soetekouw, T. R. Jeffry Evans, Marianne Nicolson, Jan H. M. Schellens*, Maria Learoyd, Lynda Grinsted, Victoria Zazulina, Thinn Pwint, Mark Middleton

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

32 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1619-1628
JournalCancer Chemotherapy and Pharmacology
Issue number6
Publication statusPublished - Dec 2011


  • MEK 1/2 inhibitor
  • Selumetinib
  • Phase I
  • Food effect

Cite this